Be a Smart Investor

Friday, November 1, 2019

AIG Confident Of Delivering Underwriting Profitability In 2019 - Quick Facts

While reporting financial results for the third quarter on Friday, insurer American International Group, Inc. (AIG) said as it approaches 2020, it remains confident it will deliver underwriting profitability for the full year 2019 and deliver double-digit Return on Common Equity (ROCE) by the end of 2021.

from RTT - Earnings https://ift.tt/2PC8Cyo
via IFTTT

Newell Brands Boost FY19 Normalized EPS, Net Sales Outlook - Quick Facts

While reporting financial results for the third quarter on Friday, consumer goods company Newell Brands (NWL) raised its normalized earnings and net sales guidance for the full-year 2019, based on the stronger than anticipated performance thus far in the year. The company also provided outlook for the fourth quarter.

from RTT - Earnings https://ift.tt/2C7Qd4h
via IFTTT

Healthcare Stocks That Hit New Highs ( REPH, CNMD, DRNA,...)

The following are the healthcare stocks that hit a new 52-week high on Thursday.

from RTT - Biotech https://ift.tt/325igfl
via IFTTT

Will Mirum Pharma Reverse Course?

Shares of Mirum Pharmaceuticals Inc. (MIRM) are down nearly 46% since their market debut on July 18, 2019.

from RTT - Biotech https://ift.tt/2WyOn67
via IFTTT

Haemonetics Boosts FY20 Adj. EPS Outlook - Quick Facts

While reporting financial results for the second quarter on Friday, healthcare company Haemonetics Corp. (HAE) raised its adjusted earnings guidance for the full-year 2020, while reaffirming annual revenue growth outlook.

from RTT - Earnings https://ift.tt/2Py2cjM
via IFTTT

Keep An Eye On QRVO, FTNT, BRKR.

Keep An Eye On QRVO, FTNT, BRKR.

from RTT - Earnings https://ift.tt/2N9b3a5
via IFTTT

BGNE Soars, DRNA Hits New High On Roche Deal, FDA Heeds REPH's Request

Today's Daily Dose brings you news about the reverse split of Applied DNA; the global strategic oncology collaboration between BeiGene and Amgen; better-than-expected earnings reported by Bio-Rad; upcoming catalysts of bluebird bio; licensing agreement between Dicerna Pharma and Roche; and an update on Recro Pharma's intravenous (IV) Meloxicam.

from RTT - Biotech https://ift.tt/2N4IJ8J
via IFTTT